References
- Vasudevan B, Neema S, Verma R. Livedoid vasculopathy: a review of pathogenesis and principles of management. Indian J Dermatol Venereol Leprol. 2016;82(5):478–488.
- Pulido-Perez A, Aviles-Izquierdo JA, Suarez-Fernandez R. Cutaneous vasculitis. Actas Dermo-Sifiliograficas. 2012;103(3):179–191.
- Micieli R, Alavi A. Treatment for livedoid vasculopathy: a systematic review. JAMA Dermatol. 2018;154(2):193–202.
- Provenza JR, Pedri LE, Provenza GM. Livedoid vasculopathy. Rev Bras Reumatol. 2016;56(6):554–556.
- Monshi B, Posch C, Vujic I, et al. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients. J Am Acad Dermatol. 2014;71(4):738–744.
- Lee SS, Ang P, Tan SH. Clinical profile and treatment outcome of livedoid vasculitis: a case series. Ann Acad Med Singap. 2003;32(6):835–839.
- Yong AA, Tan AW, Giam YC, et al. Livedoid vasculopathy and its association with factor V Leiden mutation. Singapore Med J. 2012;53(12):e258–e260.
- Hairston BR, Davis MD, Pittelkow MR, et al. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142(11):1413–1418.
- Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134(4):447–452.
- Vena GA, Cassano N, Piaserico S, et al. Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacol Immunotoxicol. 2012;34(6):901–906.
- Lockwood SJ, Prens LM, Kimball AB. Adverse reactions to biologics in psoriasis. Curr Probl Dermatol. 2018;53:1–14.
- Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–31.e15.